Catalyst’s Firdapse Pharma Product Launch Plan

Catalyst Pharmaceuticals Positioned for Success

Reality testing: Catalyst, a biopharmaceutical company, needed to prepare an FDA-designated “Breakthrough Therapy” for commercialization. FIRDAPSE (amifampridine) Tablets 10mg, was specifically designed to improve the lives of patients suffering from Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndrome (CMS), rare neuromuscular diseases. Additionally, Catalyst needed to reposition and increase the visibility of their company, while elevating physicians’ interest in identifying LEMS patients and enrolling them in their FIRDAPSE Expanded Access Program, an ongoing clinical trial that would help demonstrate product efficacy and safety.

Envisioning a new reality: REALITYRx had four clear objectives in mind: to effectively reinvent Catalyst, educate physicians about LEMS, raise awareness of their life-changing product, and prepare the market for the launch of this “Breakthrough Therapy” in 2016.

Inventing the reality: In less than one year, REALITYRx created a new corporate identity that conveyed Catalyst’s far-reaching potential. This included updating their brand—from logo to message platform. This initiative worked in tandem with the implementation of pre-launch FIRDAPSE activities, with market testing and product positioning and continued with a series of ongoing educational materials.


FIRDAPSE 3-D MOA Video Graphics

This digital video clearly demonstrated selective activity, helping healthcare professionals appreciate the unique difference of this breakthrough treatment.

FIRDAPSE Expanded Access Program (EAP)

REALITYRx developed three targeted brochures, explaining the advantages of participating in the Catalyst-sponsored EAP.

AANEM Exhibit Panel Display

An informative session revealed clinical features and breakthrough data in the treatment of LEMS.


eBlast Announcements

The larger neurology community was reached through E-blasts, scheduled before and after the AANEM forum, announcing pivotal phase III trial results.

LEMS Patient Video

A testimonial video captured the real-life story of a LEMS patient’s arduous journey from diagnosis to her life-changing treatment with FIRDAPSE.




Catalyst Pharmaceuticals Positioned for Success

Reality testing: Catalyst, a biopharmaceutical company, needed to prepare an FDA-designated “Breakthrough Therapy” for commercialization. FIRDAPSE (amifampridine) Tablets 10mg, was specifically designed to improve the lives of patients suffering from Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndrome (CMS), rare neuromuscular diseases. Additionally, Catalyst needed to reposition and increase the visibility of their company, while elevating physicians’ interest in identifying LEMS patients and enrolling them in their FIRDAPSE Expanded Access Program, an ongoing clinical trial that would help demonstrate product efficacy and safety. Envisioning a new reality: REALITYRx had four clear objectives in mind: to effectively reinvent Catalyst, educate physicians about LEMS, raise awareness of their life-changing product, and prepare the market for the launch of this “Breakthrough Therapy” in 2016. Inventing the reality: In less than one year, REALITYRx created a new corporate identity that conveyed Catalyst’s far-reaching potential. This included updating their brand—from logo to message platform. This initiative worked in tandem with the implementation of pre-launch FIRDAPSE activities, with market testing and product positioning and continued with a series of ongoing educational materials.


FIRDAPSE 3-D MOA Video Graphics

This digital video clearly demonstrated selective activity, helping healthcare professionals appreciate the unique difference of this breakthrough treatment.

FIRDAPSE Expanded Access Program (EAP)

REALITYRx developed three targeted brochures, explaining the advantages of participating in the Catalyst-sponsored EAP.

AANEM Exhibit Panel Display

An informative session revealed clinical features and breakthrough data in the treatment of LEMS.


eBlast Announcements

The larger neurology community was reached through E-blasts, scheduled before and after the AANEM forum, announcing pivotal phase III trial results.

LEMS Patient Video

A testimonial video captured the real-life story of a LEMS patient’s arduous journey from diagnosis to her life-changing treatment with FIRDAPSE.

Share This